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The human immunodeficiency virus type 1 (HIV-1) develops resistance to all available drugs, including the nucleoside
analog reverse transcriptase inhibitors (NRTIs) such as AZT. ATP-mediated excision underlies the most common form of
HIV-1 resistance to AZT. However, clinical data suggest that when HIV-2 is challenged with AZT, it usually accumulates
resistance mutations that cause AZT resistance by reduced incorporation of AZTTP rather than selective excision of
AZTMP. We compared the properties of HIV-1 and HIV-2 reverse transcriptase (RT) in vitro. Although both RTs have
similar levels of polymerase activity, HIV-1 RT more readily incorporates, and is more susceptible to, inhibition by
AZTTP than is HIV-2 RT. Differences in the region around the polymerase active site could explain why HIV-2 RT
incorporates AZTTP less efficiently than HIV-1 RT. HIV-1 RT is markedly more efficient at carrying out the excision
reaction with ATP as the pyrophosphate donor than is HIV-2 RT. This suggests that HIV-1 RT has a better nascent ATP
binding site than HIV-2 RT, making it easier for HIV-1 RT to develop a more effective ATP binding site by mutation. A
comparison of HIV-1 and HIV-2 RT shows that there are numerous differences in the putative ATP binding sites that
could explain why HIV-1 RT binds ATP more effectively. HIV-1 RT incorporates AZTTP more efficiently than does HIV-2
RT. However, HIV-1 RT is more efficient at ATP-mediated excision of AZTMP than is HIV-2 RT. Mutations in HIV-1 RT
conferring AZT resistance tend to increase the efficiency of the ATP-mediated excision pathway, while mutations in
HIV-2 RT conferring AZT resistance tend to increase the level of AZTTP exclusion from the polymerase active site. Thus,
each RT usually chooses the pathway best suited to extend the properties of the respective wild-type enzymes.
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Introduction
Although considerable progress has been made in devel-
oping successful anti-human immunodeﬁciency virus type 1
(HIV-1) drugs and drug therapies, there are serious problems
with drug toxicity and the development of drug-resistant viral
strains. HIV-1 can develop resistance to all 21 of the currently
approved drugs to treat it. Of these 21 drugs, 13 inhibit the
virally encoded reverse transcriptase (RT). The available RT
inhibitors can be divided into two classes: nucleoside reverse
transcriptase inhibitors (NRTIs) and nonnucleoside inhib-
itors (NNRTIs). Both classes of inhibitors block the polymer-
ase activity of RT. NNRTIs bind in a hydrophobic pocket in
HIV-1 RT near the polymerase active site. A bound NNRTI
does not block the binding of either the nucleic acid substrate
or the incoming 39-deoxynucleotide triphosphate (dNTP);
however, it does block the chemical step of polymerization.
NRTIs are analogs of the normal nucleotides used to
synthesize viral DNA; however, NRTIs lack a normal 39-OH,
and, as a consequence, act as chain terminators when
incorporated into viral DNA by RT. Most NRTIs are given
to patients in an unphosphorylated state (the exception is
tenofovir, a nucleotide analog that is given as a pro-drug).
NRTIs must be taken up by cells and phosphorylated by
cellular enzymes before they can be incorporated by RT [1]
and references in [1].
Resistance to NRTIs is caused by mutations in HIV-1 RT.
Resistance implies that the mutant RT has an enhanced
ability to discriminate between the NRTI and normal
nucleosides compared to wild-type RT. There are two
different ways in which this increased discrimination can
occur: 1) the mutant RT incorporates the NRTI triphosphate
(NRTITP) less efﬁciently than does the wild-type RT; 2) the
mutant RT is more efﬁcient at selectively excising the
nucleoside analog reverse transcriptase inhibitor triphos-
phate (NRTIMP) after it has been incorporated into viral
DNA than is wild-type RT. Both mechanisms are used by
NRTI-resistant HIV-1 mutants. For example, the M184V
mutation selectively interferes with the incorporation of
3TCTP by steric hindrance [1]. In contrast, the most common
form of AZT resistance (which usually involves some
combination of the mutations M41L, D67N, K70R, T215F/Y,
and K219E/Q) causes the selective excision of AZTMP [1–4].
We have developed a model that explains the mechanism
that underlies the selective excision of AZTMP by AZT-
resistant HIV-1 RT [3]. HIV-1 RT does not have a separate
nuclease activity that carries out AZTMP excision; the
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run in reverse. If the polymerase reaction is run in reverse,
the products of the polymerization reaction (the elongated
DNA primer and pyrophosphate) are brought back together
at the polymerase active site, and the last nucleotide at the 39
end of the primer is joined to pyrophosphate, regenerating a
dNTP and shortening the primer by one nucleotide. In the
excision reaction that causes AZT resistance in vivo, the
pyrophosphate donor is ATP, and the reaction that removes
the last nucleotide from the primer generates a dinucleoside
tetraphosphate [1,3,4]. The model resolves two important
questions: 1) How do the mutations in HIV-1 RT cause AZT
resistance? 2) Why is excision much more efﬁcient for AZT
than for other NRTIs? The canonical AZT-resistance muta-
tions cause AZT resistance because they enhance the ability
of HIV-1 RT to bind ATP appropriately, thus enhancing the
excision reaction. The reason AZTMP is excised much more
efﬁciently than other NRTIMPs is that it has better access to
the nucleotide binding site (N site), where excision can occur
[3]. However, the virus can acquire additional mutations that
enhance its ability to excise a broader range of NRTIs. The
most common of these are insertions in the ﬁngers
subdomain (usually an insertion of two amino acids between
positions 69 and 70, accompanied by mutations at what were
originally amino acids 69 and 70). The ﬁngers insertion
mutations appear to give NRTIMP-terminated primers better
access to the N site, where the NRTIMP can be excised [5–7].
The excision mechanism accounts for the vast majority of
HIV-1 AZT resistance; however, in some cases, particularly in
cases in which patients were treated with AZT in combination
with ddI and ddC, HIV-1 develops resistance via the Q151M
mutation. This mutation has been observed in only 5% of the
patients treated with NRTIs, but the Q151M mutation, by
itself, appears to have only a slight deleterious effect on the
polymerase activity of RT [1]. The Q151M mutation interferes
with the incorporation of AZTTP rather than enhancing the
excision of AZTMP [1,8–10].
Although far fewer HIV-2–infected patients have been
treated with AZT, it appears that the predominant pathway
for AZT resistance in HIV-2 involves mutations at Q151
(usually Q151M; however Q151I and Q151L mutations have
been reported) rather than the excision pathway, and it has
been suggested that the preferred pathways for AZT
resistance may be different for the two viruses [11–16]. We
have used biochemical analysis and structural comparisons to
try to understand why these two related viruses prefer to use
different AZT resistance mechanisms. In simple polymerase
assays, HIV-1 RT and HIV-2 RT have similar levels of
polymerase activity. Wild-type HIV-1 RT readily incorporates
AZTTP, but it also removes AZTMP from the end of a blocked
primer relatively efﬁciently using an ATP-mediated excision
reaction [1–4]. In contrast, wild-type HIV-2 RT incorporates
AZTTP less efﬁciently; but is also less efﬁcient in removing
AZTMP in an ATP-mediated excision reaction. This suggests
that HIV-1 RT has a better nascent ATP binding site than
HIV-2 RT. A comparison of the structures of HIV-1 RT and
HIV-2 RT shows that there are a number of signiﬁcant
differences in the region that forms the putative ATP binding
site [3] that could account for the difference in the ability of
the two enzymes to bind ATP for the excision reaction. As
mentioned above, HIV-2 RT incorporates AZTTP less
efﬁciently than HIV-1 RT. We compared the regions around
the polymerase active site and dNTP binding site (with a
particular focus on Q151) in HIV-1 RT and HIV-2 RT to try
to account for this difference. There are modest differences
in this region that suggest that there are differences in the
details of how the two RTs interact with an incoming dNTP.
Some of these differences could contribute to the preference
HIV-2 RT shows for choosing the Q151M pathway for AZT
resistance.
Results
Comparing HIV-1 RT and HIV-2 RT
There are published data to suggest that HIV-1 RT and
HIV-2 RT have similar levels of polymerase activity [17,18].
To conﬁrm this, we measured the polymerase activities of
HIV-1 RT and HIV-2 RT. We found that the two enzymes
have similar activities in standard assays; it appears that HIV-
2 RT is slightly less active in a simple polymerase assay (;75%
of HIV-1 RT) and slightly less processive than HIV-1 RT on a
single-stranded M13 DNA template (Figure 1). We also
compared the RNase H activities of the two enzymes; as
expected from the published data, HIV-1 RT has a more
active RNase H than HIV-2 RT (unpublished data). We
measured the ability of HIV-1 RT to incorporate AZTTP in a
simple polymerase assay: HIV-1 RT is signiﬁcantly more
susceptible to inhibition by AZTTP than is HIV-2 RT (Figure
2). This is in agreement with a recent study suggesting that
HIV-1 viral replication is more sensitive to AZT than is HIV-2
[16]. We also measured the kinetics of incorporation of dTTP
and AZTTP in a single nucleotide incorporation assay (Table
1). HIV-1 RT had a higher kcat and a lower Km for both dTTP
and AZTTP compared with HIV-2 RT (Table 1). Because AZT
is poorly phosphorylated by cellular kinases, the differences
in the Km for AZTTP may be particularly important and may
account for the difference in susceptibility of the two
enzymes to inhibition by AZTTP (see Discussion).
We examined the effects of the Q151M mutation on both
HIV-1 RT and HIV-2 RT activities. Both wild-type HIV-1 RT
and the HIV-1 RT containing Q151M had similar polymerase
activity when M13mp18 DNA was used as the template (the
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Synopsis
Although a number of useful drugs have been developed to treat
HIV-1 infections, the virus can become resistant to all of the drugs.
Resistance involves the acquisition of mutations in the part of the
virus that is the drug target. AZT resistance involves mutations in the
viral enzyme reverse transcriptase (RT); RT copies the viral genetic
information from RNA into DNA. HIV-1 can develop AZT resistance in
two ways; each resistance pathway is characterized by distinct RT
mutations. One of the pathways is used by the vast majority of AZT-
resistant viruses isolated from patients. However, the closely related
virus HIV-2 appears to use the other pathway more frequently than
HIV-1. The authors compared the structures and biochemical
properties of HIV-1 and HIV-2 RT to try to understand why these
two related viruses acquire different AZT-resistance mutations.
Although the two RTs are biochemically and structurally similar,
there are differences in the respective wild-type RTs, and each can
be considered to be part way along the two different resistance
pathways. For this reason, it is easier for each virus to acquire the
mutations that allow it to use the resistance pathway that extends
the properties of the respective wild-type RTs.Q151M variant had 105% of the activity of wild type HIV-1
RT). As expected, the Q151M mutation decreased the
sensitivity of HIV-1 RT to AZTTP (Figure 2). In HIV-2 RT,
the Q151M mutation had a small effect on polymerase
activity (93% of the activity of the wild-type HIV-2 RT) in the
M13mp18 polymerase assay. However, the Q151M mutation
made HIV-2 RT relatively resistant to AZTTP (Figure 2).
We also ran the polymerase reaction in reverse (as part of
an excision/extension assay with pyrophosphate as the
pyrophosphate donor). HIV-1 RT is slightly more active in a
simple polymerization assay; however, it also incorporates
AZTTP more readily than HIV-2 RT, and it might be
expected to excise AZTMP more readily in a pyrophos-
phate-based excision assay. Because the excision/extension
assay involves both incorporation and excision, these factors
are likely to balance out. As Figure 3A shows, HIV-1 RT and
HIV-2 RT behave similarly when pyrophosphate is used in an
excision/extension assay. However, when ATP was used as the
pyrophosphate donor in an excision/extension assay, HIV-1
RT was markedly more efﬁcient at removing AZTMP from
the end of a blocked primer (Figure 3B). Given the fact that
the two enzymes showed equivalent levels of AZTMP excision
in a similar assay with pyrophosphate as the donor, this result
suggests that HIV-1 RT has a better nascent ATP binding site
than HIV-2 RT. To test this hypothesis, we compared the
structure of the putative ATP binding site of HIV-1 RT with
the equivalent region of HIV-2 RT using the recently
published structure of HIV-2 RT [19,20].
Comparing the Putative ATP Binding Sites of HIV-1 RT and
HIV-2 RT
Figure 4 shows a comparison of the amino terminal
sequences of the RTs of HIV-1 strain BH10 and HIV-2 strain
ROD, which are the strains used in this analysis. Figure 5
shows a comparison of the putative ATP binding sites of HIV-
1 RT and HIV-2 RT. There are a number of differences in the
structures. Prominent differences are seen in the portions of
the large subunit that form the putative ATP binding pocket.
These include: 1) the amino terminus of the RT; 2) the loop
that includes amino acids 115–118; 3) the segment that
contains amino acids 214 and 215; 4) the region around
amino acid 219; and 5) the segment that includes amino acids
41–46.
Figure 1. Processivity of Wild-Type HIV-1 and HIV-2 RTs
As described in Materials and Methods, a 59 end-labeled primer was
annealed to single-strand M13mp18 DNA, then extended with wild-type
HIV-1 RT or HIV-2 RT in the presence of 10.0 lM of each dNTP and
unlabeled poly(rC) oligo(dG), which acts as a ‘‘cold trap.’’ The cold trap
limits extension to one round of polymerization. The location of the size
marker bands (in nucleotides) are shown on the left.
DOI: 10.1371/journal.ppat.0020010.g001
Figure 2. Inhibition of RT Polymerization by AZTTP
The assay was done as previously described [1]. Normal dNTPs were
present in the reaction at 10.0 lM each. Increasing concentrations of
AZTTP were added, and the level of radioactive [a 
32P]dCTP incorpo-
rated into the template/primer was measured. The level of radioactivity
incorporated in the absence of analog was considered 100% activity; the
other reactions were normalized to this value. The error bars are
included; however, they are partially obscured by the data symbols. RT1
and RT2 designate the HIV RT backbone in which the Q151M mutation
was made: HIV-1 or HIV-2.
DOI: 10.1371/journal.ppat.0020010.g002
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There are a number of differences in the ﬁrst 10 amino
acids of HIV-1 RT and HIV-2 RT (Figure 4). Amino acids 1
and 6 are conserved and 2, 5, 7, and 10 are either V or I; the
other amino acids are quite different in the two RTs. The
amino terminus of the p66 subunit of HIV-1 RT forms the
lower part of the putative ATP binding pocket, and helps to
organize the segments on the left and right sides of the pocket
(Figures 5 and 6). In the vast majority of HIV-1 RT structures,
the amino terminus of p66 is tightly associated with the rest
of the protein, which helps to deﬁne and stabilize the ATP
binding pocket. The interaction between the amino terminus
of p66 and the rest of HIV-1 RT involves a hydrogen bond
between residue 3 of the amino terminus and residue 117 of
the ﬁngers subdomain, and additional interactions between
residues 2 (and sometimes residue 3) of the amino terminus
and residue 213 of the palm subdomain. These interactions
vary slightly among the different HIV-1 RT structures; we
compared the structures of unliganded HIV-1 RT, complexes
with NNRTIs, and complexes with nucleic acid substrates. In
the structure of unliganded HIV-2 RT, there is much less
contact between the amino terminus of the large subunit and
the body of the protein, and there are no corresponding
hydrogen bonds [20]. It should be pointed out that neither
the HIV-1 RT nor the HIV-2 RT used to generate the crystal
structures shown in Figure 6 have the same amino acids at the
amino terminus that are present in the corresponding virally
produced enzymes. Both recombinant RTs have the normal
amino terminus extended by two amino acids (MV in both
cases). However, in neither case are the added MV residues
visible in the crystal structures. Instead, the ﬁrst visible amino
acid in the large subunit of the majority of the HIV-1 RT
crystal structures corresponds to amino acid 1 of virally
produced HIV-1 RT. There are structures (including 1FK9,
1COT, and 1EP4) in which amino acid 4 of virally produced
RT is the ﬁrst visible residue at the N terminus. The ﬁrst
visible residue at the N terminus of the large subunit of HIV-2
RT is virally encoded residue 3. In both HIV-1 and HIV-2 RTs
the predicted position of the two engineered residues (MV) is
not likely to directly affect the formation of the ATP binding
pocket [1]. This suggests that the two additional amino acids
(MV), which were introduced to facilitate the expression of
the HIV-1 RT and HIV-2 RT proteins in Escherichia coli, do not
markedly affect either structure.
The Loop That Includes 115–118
The segment that includes amino acids 110–120 is quite
conserved in HIV-1 RT and HIV-2 RT; there is only one
modest change, at position 118. In HIV-1 RT, 118 is V; in
HIV-2 RT, 118 is I (Figure 4). The loop that includes 115–118
is displaced in the larger subunit of HIV-2 RT relative to its
position in HIV-1 RT; the loop lies farther from D185 in HIV-
2 RT than in HIV-1 RT (see Figure 6). Not only is there a
displacement of the amino acid backbone, but there are also
substantial differences in the positions of the amino acid side
chains of 113, 116, and 117. This may result, in part, from the
fact (already mentioned) that there is, in HIV-1 RT, a
hydrogen bond between amino acids 3 and 117; this hydrogen
Table 1. Summary of the Single Nucleotide Incorporation
Kinetics Assay
Substrate Enzyme Km kcat
[S] ¼ dTTP HIV-1 RT 3.5 6 0.6 3.5 6 0.4
HIV-2 RT 11.9 6 1.0 1.0 6 0.03
[S] ¼ AZTTP HIV-1 RT 0.17 6 0.03 3.5 6 0.23
HIV-2 RT 0.75 6 0.21 1.6 6 0.24
Template/primer was incubated with various concentrations of substrate ([S]; lM dTTP or AZTTP) and the
amount of product ([P]; nM primer þ 1) produced in a 1-min reaction time was determined using a
PhosphoImager. Km is in lM dTTP or AZTTP. kcat is the turnover number and is defined as Vmax (the
maximum velocity of the reaction; expressed as nM primer þ 1 generated in 1 min) divided by [Etotal],
which in this assay is 3.0 nM RT. The turnover number indicates the nM of product (primerþ1) produced
by each nM of active site (for RT, this equals 1) in 1 min (nM P nM RT
 1 min
 1). The assay was done three
separate times for each enzyme and each substrate and the results averaged.
DOI: 10.1371/journal.ppat.0020010.t001
Figure 3. Excision/Extension of AZTMP by HIV-1 RT and HIV-2 RT
As described in Materials and Methods, a 59 end-labeled primer was
annealed to a template. The 39 end of the primer was blocked by the
addition of AZTMP.
(A) The excision/extension assays were performed with AZTMP-blocked
primers in the presence of high levels of dNTPs (100.0 lM each), which
favors formation of the ternary complex (RT/DNA/dNTP) and the
indicated concentrations of NaPPi (50.0, 100.0, 200.0 lM). All experiments
were done at least in duplicate; a typical result is shown.
(B) Excision/extension of an AZTMP-blocked primer using high levels of
dNTPs (100.0 lM each dNTP) and the indicated concentrations of ATP
(2.0, 5.0, 10.0 mM). All experiments were done at least in duplicate; a
typical result is shown.
DOI: 10.1371/journal.ppat.0020010.g003
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of 113 lies in front of 116 and 117 and lies somewhat between
them. In HIV-2 RT 113 lies above the side chains of 116 and
117, which are much closer to each other than in HIV-1 RT.
In HIV-2 RT, it appears that these differences, in particular
the positions of the side chains of 113 and 116, would make
the putative ATP binding pocket shallower and less able to
bind ATP appropriately for the excision reaction.
Segment That Includes 214 and 215
The segment from 213 to 218 is moderately well conserved
when HIV-1 RT is compared to HIV-2 RT (Figure 4). In HIV-2
RT amino acid 214 is an F. In some, but not all, B subtype
HIV-1 strains (including BH10, which was used to make the
recombinant RTs from which the structures were derived),
amino acid 214 is an L. In many other HIV-1 subtypes the
predominant amino acid at 214 is an F. HIV-1 RT has a T at
position 215; HIV-2 RT an S (Figure 4). In the development of
an excision-proﬁcient HIV-1 RT, T215F/Y is a key mutation.
For the HIV-1 isolate BH10 used in these experiments, the
codon for T215 is ACC. Mutation to either phenylalanine
(TTC) or tyrosine (TAC) would require two nucleotide
substitutions. In contrast, the codon for S215 in HIV-2 RT
can be TCT (e.g., strains ROD and D194) or TCC (e.g., strain
SBLISY). A single nucleotide change is sufﬁcient to convert
this codon to F (TTT or TTC) or Y (TAT or TAC). Even
though it is simpler to change the amino acid at 215 to an F or
Y in HIV-2 than in HIV-1 (see below), this mutation does not
appear to be the favored pathway for the development of
AZT resistance in HIV-2. The aromatic residue (either F or Y)
at 215 in the p66 subunit of HIV-1 RT is thought to interact
with the adenine ring of ATP. This suggests that the position
of the amino acid side chain at position 215 (relative to the
polymerase active site) would be crucial for ATP binding and
excision. In both HIV-1 and HIV-2 RT, the position of the 215
side chain appears to be affected by the interaction between
residues 214 and 118. In HIV-1 RT, V118 and L214 make a
hydrophobic interaction. In HIV-2 RT, the corresponding
residues are larger (F214 and I118) and the interaction results
in repositioning of the corresponding segments. As a result,
the side chain of S215 is closer to the active site of HIV-2 RT
than is the corresponding T215 of HIV-1 RT, and the position
of the S215 of HIV-2 RT is stabilized by a hydrogen bonding
interaction with the main chain at position 112 (Figure 6).
The larger F at 214 of HIV-2 RT may not only affect the
position of the side chain of 215 but also contribute to the
shallowness of the putative ATP binding pocket in HIV-2 RT
(and potentially in those HIV-1 isolates that have an F at this
position). In comparing the ability of wild-type HIV-1 RT and
HIV-2 RT to carry out ATP-mediated AZTMP excision, it is
worth noting that the threonine present at position 215 in
HIV-1 RT is modestly more hydrophobic than is the serine
found at 215 in HIV-2 RT. Because of the importance of the
T215F/Y mutation, even this small difference in hydro-
phobicity, coupled with the more favorable position of the
T215 side chain, would enhance the ability of wild-type HIV-1
RT to bind ATP appropriately for excision relative to wild-
type HIV-2 RT.
The Region around 219
The amino acids from 216–220 are conserved, except for
219, which is K in HIV-1 RT and E in HIV-2 RT (Figure 4).
Figure 4. Comparison of the First 240 Amino Acids of HIV-1 RT (Strain BH10) and HIV-2 RT (Strain ROD)
The triad of aspartic acid residues critical for polymerase activity is shown in red. The amino acid residues that are altered as part of the Q151M complex
in HIV-1 RT are shown in blue; residues 214, 215, and 219 are shown in plum.
DOI: 10.1371/journal.ppat.0020010.g004
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RT, a transposition of the amino acid backbone of HIV-2 RT
relative to HIV-1 RT so that amino acid 219 of HIV-2 RT is
much closer to D185 than it is in HIV-1 RT (Figure 7). This
shift also causes the approximate alignment of K219 in HIV-1
RT with K220 of HIV-2 RT (Figure 7). It is not clear whether
this difference would affect ATP-mediated excision, and, if it
does, whether the effect of moving E219/K220 in HIV-2 RT
relative to the active site would be favorable or unfavorable
for excision. This difference in the region around 219 may be
connected to changes seen in the loop that carries the active
site amino acids 185 and 186 (Figure 7). The only available
HIV-2 RT structure is unliganded (there is, in the structure,
no bound inhibitor, nucleic acid, or incoming dNTP) [19,20].
In HIV-1 RT, a comparison of the available structures,
unliganded and liganded, shows that binding an incoming
dNTP appears to cause the 185–186 loop (b9–b10) to move
‘‘down’’ relative to the position of the nucleic acid (Figure 7).
The binding of tenofovir diphosphate at the polymerase
active site moves the 185/186 loop down and also brings the
side chain of 219 down toward 185/186 (Figure 7), relative to
the position the 219 side chain occupies when a normal dNTP
is bound [21]. Despite the fact that the HIV-2 RT structure
was generated with an unliganded protein, the 185/186 loop is
in a ‘‘down’’ position relative to unliganded HIV-1 RT. As has
already been pointed out, the backbone position of K219 in
HIV-1 RT is approximately the same as the backbone position
of K220 in HIV-2 RT. These changes could affect ATP-
mediated excision reaction. If these speciﬁc interactions
affect the ability of HIV-2 RT to bind ATP in a favorable way,
the interactions would have to involve portions of ATP other
than the beta and gamma phosphates because any unfavor-
Figure 5. Polymerase Active Site Regions of HIV-1 RT and of HIV-2 RT
(A) The HIV-1 RT complex with an AZTMP-terminated primer trapped at
the N site (PDB code 1N6Q).
(B) Nucleic acid from (A) superposed on the structure of unliganded HIV-2
RT (PBD code 1MU2). The side chains of amino acid residues proximal to
the azido group of AZTMP are shown as white spheres, which represent
the Van der Waals volumes. The side chains of amino acid residues at the
interface of several secondary structure elements of RT are shown in
different colors: 209–215 of the large subunit (green spheres), 41–46 of
the large subunit (magenta spheres), 116–117 of the large subunit (red
spheres), and the N-terminus of the large subunit (cyan spheres). The
proposed ATP-binding regions are shown as semitransparent yellow
ellipsoids. The direction of the nucleophilic attack of ATP on the AZTMP-
terminated primer is indicated by a black arrow.
DOI: 10.1371/journal.ppat.0020010.g005
Figure 6. A Comparison of the Structure of an HIV-1 RT/DNA Complex
with the Structure of Unliganded HIV-2 RT
In the HIV-1 RT complex (PDB code 1N6Q), shown in yellow, the 39 end of
the primer is in the N site, unliganded HIV-2 RT (PDB code 1MU2) is
shown in magenta. The residues used for the superposition were
1079112 and 1559215. The Van der Waal radii for the atoms in the amino
acid residues at positions 117 and 214 are shown as spheres: yellow for
HIV-1 RT and blue for HIV-2 RT. The superposition highlights two major
differences between the two enzymes: a) the interaction between the N
terminus and residue Ser117 of p66 in HIV-1 RT (red dotted line) is absent
in HIV-2 RT because in HIV-2 RT the N terminus has moved away from
residue 117 (cyan dotted line); b) in HIV-1 RT, Ser117 interacts with
Leu214 1 RT in a way that differs from the interaction of Ser117 and the
bulkier Phe214 in HIV-2 RT.
DOI: 10.1371/journal.ppat.0020010.g006
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interfere with the polymerization reaction. In the polymer-
ization reaction, the gamma and beta phosphates of the
incoming dNTP are expected to interact with RT at positions
that are very similar to the positions where the beta and
gamma phosphates of ATP are believed to bind in the
excision reaction. As has already been discussed, HIV-2 RT is
a fully competent polymerase and carries out pyrophosphate-
mediated excision with an efﬁciency similar to HIV-1 RT.
The Segment That Includes 41–46
Amino acids 41–45 are conserved between HIV-1 RT and
HIV-2 RT; however, amino acids 46–50 are not (Figure 4).
Residue 46 is K in HIV-1 RT; it is Q in HIV-2 RT. When the
two structures are compared, the relative arrangements of the
amino acid side chains in the larger subunit at positions 41,
44, and 46 are quite different. In HIV-1 RT, 44 and 46 lie close
together near the lower end of the ATP binding pocket. In
HIV-2 RT, 41 lies next to 44, but 46 is displaced well away
both from 44 and from the putative ATP binding pocket.
These differences appear to be connected to the changes in
the amino terminus, which lies close to 44 and 46. There are
good reasons to think that both 41 and 44 (as well as 118) may
play a role in positioning ATP for excision in HIV-1 RT.
M41L is one of the canonical mutations involved in AZT
resistance in HIV-1 RT; this suggests that amino acid 41 plays
a direct or indirect role in ATP binding. HIV-1 RT carrying
the canonical mutations associated with AZT resistance
(M41L, D67N, K70R, T215F/Y, K219Q) excises AZTMP
efﬁciently, but cannot excise 3TCMP to any signiﬁcant
extent. The addition of E44D and V118I confers 3TC
resistance in the absence of the M184V mutation, apparently
by enhancing 3TCMP excision, suggesting that these muta-
tions affect the positioning of ATP and, as a result, the
efﬁciency of 3TCMP excision [1].
A Comparison of the Regions around Q151 in HIV-1 RT
and HIV-2 RT
In the sections presented above, the differences between the
activity and structure of HIV-1 RT and HIV-2 RT were
considered in light of their effects on the putative ATP
binding site. If, as we propose, wild-type HIV-2 RT binds ATP
less efﬁciently than wild-type HIV-1 RT, this would explain
why HIV-2 RT does not prefer to use ATP-dependent excision
for AZT resistance. As described above, AZT resistance in
HIV-2 appears to involve the Q151M mutation, which has
been shown to affect NRTI incorporation in HIV-1 RT [1].
This mutation is occasionally selected in HIV-1 RT in
response to NRTI combination therapy; however, it has only
been observed in approximately 5% of treated patients [1]. In
contrast, in HIV-2 infected patients receiving NRTI-contain-
ing therapies, Q151M has been reported to be present in more
than 45% of the patients examined [11], and other groups
have also reported a high frequency of the Q151M mutation in
HIV-2 patients receiving NRTI therapy [13–15]. It is possible
that HIV-2 RT prefers to use the Q151M pathway for AZT
resistance, at least in part, because wild-type HIV-2 RT
incorporates AZTTP less efﬁciently, and is already partway
along a pathway leading to reduced AZTTP incorporation. It
is also possible that the Q151M mutation is more favorable in
the context of HIV-2 RT than HIV-1 RT. As discussed above,
the Q151M mutation causes an increase in resistance to
AZTTP in both HIV-1 RT and HIV-2 RT (Figure 2). However,
in part because the wild-type HIV-2 RT is already more
resistant to AZTTP than is the HIV-1 variant Q151M, the
presence of Q151M makes the HIV-2 RT highly resistant to
AZTTP (Figure 2). Position 151 is, in the larger subunit, part of
the dNTP binding site and we compared this region in the two
RTs (Figure 8). Because Q151 is in a region of the large subunit
that interacts with both the nucleic acid and the incoming
dNTP, we compared the structure of unliganded HIV-2 RT to
both an unliganded HIV-1 RT structure and to an HIV-1 RT
structure that contains both a bound DNA and an incoming
dNTP. We considered the position of 151 itself and the
segment that contains 151. We reexamined the segment that
carries 113–118, which had been considered (and discussed) as
part of the analysis of the putative ATP binding site, to
investigate its role in the binding and incorporation of an
NRTITP. We also looked at the positions where secondary
mutations arise in HIV-1 RTs that acquire the Q151M
mutation (A62V, V75I, F77L, and F116Y).
The Segment That Includes Q151
The segment from148 to 161 is conserved between HIV-1
RT and HIV-2 RT (Figure 4); in addition, the Q151 residue is
in a very similar position in the two RTs. In the ternary
complex of HIV-1 RT, Q151 is near R72, L74, Y115, and F116
(Figure 8). Q151 also interacts with the main chain at position
73. These residues form part of the dNTP binding pocket,
speciﬁcally that portion of the pocket that underlies the
Figure 7. Position of the Side Chain of Amino Acid Residue K219 in HIV-1
RT and K220 in HIV-2 RT
Unliganded HIV-2 RT (shown in magenta; PDB code 1MU2) and HIV-1 RT/
DNA/dTTP (shown in white with the dTTP and DNA omitted for clarity;
PDB code 1RTD), is superimposed on the Ca protein backbone of HIV-1
RT/DNA/tenofovir-diphosphate (shown in cyan; PDB code 1TO5). The
residues used for the superposition were 107–112 and 155–215. The
alignment shows that K220 of HIV-2 RT is the residue structurally
equivalent to K219 in HIV-1 RT.
DOI: 10.1371/journal.ppat.0020010.g007
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dNTP and, through R72, with the phosphates. Because a 29,39-
dideoxynucleotide triphosphate (ddNTP) lacks the 39-OH
that Q151 would normally interact with, the network of
hydrogen bonds differs in a complex with a ddNTP and Q151
interacts only with R72 [1]. The substitution of a methionine
for the glutamine normally present at 151 enhances the
ability of the enzyme to discriminate against the incorpo-
ration of nucleoside analogs that lack a 39-OH [1,8–10].
Although we do not have a ternary structure of HIV-2 RT, it is
likely, because the Q151 residue and its immediate environ-
ment are similar in the two RTs, and because the resistance
mutations are the same (Q151M), that the underlying
resistance mechanism is the same. In the case of HIV-1, RTs
that carry the Q151M mutation are less sensitive to AZTTP
and ddNTPs than wild-type RT, and the addition of
secondary mutations (A62V, V75I, F77L, and F116Y) causes
a further decrease in the sensitivity to these analogs. The
ﬁtness cost, if any, of the Q151M mutation in HIV-2 is not
known (discussed below).
The Segment That Includes 113–118
Despite the fact that the sequence of the segment that
carries 113–118 is conserved between HIV-1 RT and HIV-2
RT, the exact position of this segment differs slightly when
unliganded HIV-1 RT is compared with the HIV-1 RT ternary
complex; however, it is displaced considerably farther in the
unliganded HIV-2 RT structure, in part because (as has
already been discussed) there is a hydrogen bond between
amino acid 3 and amino acid 117 in HIV-1 RT which does not
exist in HIV-2 RT. We do not yet have a ternary structure of
HIV-2 RT. The region that includes 113, 114, and 115, which
interact with the phosphates and the deoxyribose of the
incoming dNTP, is displaced by 1–1.5 A ˚ in HIV-2 RT (Figures
6 and 8). A comparison of HIV-1 RT and HIV-2 RT suggests
that this could alter the interactions of these amino acids with
the incoming dNTP and/or the exact position the incoming
dNTP has in the HIV-2 RT ternary complex. Alternatively, it
is possible that the binding of the incoming dNTP causes a
greater movement of this segment of HIV-2 RT than HIV-1
RT, and the positions these amino acids (and the incoming
dNTP) occupy in the HIV-2 RT ternary complex are more
similar to their positions in the HIV-1 RT ternary complex
than the positions of the amino acid side chains in the 113–
116 segment of the unliganded HIV-2 RT would suggest.
The Mutations That Accompany Q151M in HIV-1 RT
There is a family of mutations (A62V, V75I, F77L, and
F116Y) that are often found with Q151M in HIV-1 RT. The
data available in the Stanford database suggest that this suite
of mutations does not accompany the Q151M mutation in
HIV-2 RT in the same way these mutations accompany the
Q151M mutation in HIV-1 RT. In part this may be due to the
fact that there are much fewer data for AZT-resistant HIV-2
RTs. However, the structures suggest that at least some of
these secondary mutations might not have the same impor-
tance in HIV-2 RT as in HIV-1 RT. In wild-type HIV-2 RT, the
amino acid usually present at position 75 is already an
isoleucine (it is possible that the presence of I75 contributes
to the low level of AZTTP incorporation seen with wild-type
HIV-2 RT). In HIV-1 RT, F77 interacts directly with V75, and
it may be that the reason the F77L change is found in HIV-1
RT is to help compensate for the V75I mutation. Because
HIV-2 RT already has I75, the F77L change may not be
needed. The A62V mutation does not appear to have a major
effect either in the structure of HIV-2 RT or in the behavior
of HIV-1 RT. Neither position 62 nor 77 have any direct
interactions with the nucleic acid or the incoming dNTP, nor
are either of these positions in direct contact with Q151. In
contrast, it appears that the F116Y is a more important
secondary mutation. In wild-type HIV-1 RT, Q151M interacts
with R72. This interaction is important in the two different
complexes that HIV-1 RT forms with dNTPs and ddNTPs.
Substitution of a methionine for the glutamine normally
present at position 151 will alter the interaction of R72 and
Q151. The substitution of a tyrosine for the phenylalanine
normally found at position 116 in HIV-1 RT allows the
formation of a hydrogen bond between the OH of the
tyrosine and the main chain at position 73. This may help
compensate for the altered interaction between the methio-
nine at 151 and R72 in the Q151M mutant and help to
stabilize the dNTP binding pocket in the mutant HIV-1 RT.
In contrast, the position of the phenylalanine side chain of
F116 in unliganded HIV-2 RT is sufﬁciently different that,
unless there is a signiﬁcant rearrangement of this region
when an incoming dNTP binds, the F116Y mutation would
not have the same effect in HIV-2 RT that it has in HIV-1 RT.
In unliganded HIV-2 RT the side chain of 116 is so far away
from the main chain at position 73 that introducing a
tyrosine at position 116 would not create the same hydrogen
bond that can be made in the F116Y mutant of HIV-1 RT,
unless there is signiﬁcant repositioning of the segment that
carries this residue when substrate is bound (Figure 8).
Figure 8. Superposition of HIV-1 RT and HIV-2 RT Showing the Possible
Effects of a Phe116Tyr Mutation
Unliganded HIV-2 RT (PDB code 1MU2) is shown in yellow, unliganded
HIV-1RT (PDB code 1DLO) is shown in cyan, and HIV-1 RT/DNA/dTTP
(PDB code 1RTD) is shown in red. The superposition shows that a
Phe116Tyr mutation in HIV-1 RT would affect the interactions of position
116 with the main-chain carbonyl of Lys73 in the fingers subdomain of
HIV-1 RT (dotted line). However, the same mutation in HIV-2 RT is not
likely to cause similar interactions of Tyr116 with the fingers subdomain
of HIV-2 because the differences in the position of the small helix that
carries residues 115–117 in HIV-2 RT make the interaction unlikely.
DOI: 10.1371/journal.ppat.0020010.g008
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The ability of HIV-1 RT to develop resistance to AZT by the
excision pathway poses serious problems for therapy with this
NRTI. The fact that AZT-resistant HIV-1 RTs can acquire
additional mutations, for example the insertions in the ﬁngers
subdomain that allow them to excise a broad range of NRTIs,
poses a challenge for this entire class of drugs. Despite the fact
that the full development of high-level AZT resistance via the
excision pathway requires multiple mutations, and the fact
that the key mutation, T215Y/F, requires two nucleotide
changes, excision pathway is the commonly used pathway for
development of AZT resistance in HIV-1. What makes this
somewhat surprising is that the virus has an alternative: the
Q151M mutation confers resistance to AZT and arises in
patients given certain NRTI combinations (particularly AZT
in combination with ddI and ddC) [1,8–10]. Like T215Y/F, the
mutation Q151M also requires two nucleotide changes and
requires additional mutations to increase the level of
resistance to various NRTIs. What makes HIV-19s use of the
excision pathway somewhat more puzzling is this: the related
virus, HIV-2, does not appear to use the excision pathway as
frequently when challenged with AZT. Moreover, as has
already been discussed, changing S215 to either tyrosine or
phenylalanine requires only a single nucleotide change, and
thus should arise more readily in HIV-2 RT than in HIV-1 RT.
Although the number of patients is much smaller, and so the
data are not as robust, it appears that in HIV-2–resistance to
AZT usually involves the Q151M mutation, and it has been
proposed that the two viruses use different pathways to
develop AZT resistance [11–16].
We compared HIV-1 RT and HIV-2 RT both structurally
and biochemically. The biochemical analysis suggests that
wild-type HIV-1 RT is more susceptible than HIV-2 RT in
terms of incorporating AZTTP, but that HIV-1 RT has a better
nascent ATP binding site than HIV-2 RT. The structural
comparisons show that there are a number of differences in
the putative ATP binding site that can account for the
difference in the ability of these two RTs to bind ATP. In HIV-
2 RT, theputative ATP binding pocket appears tobe shallower
and less well deﬁned. This suggests that one of the reasons
HIV-1 chooses the excision pathway for AZT resistance is
because the wild-type enzyme already has a nascent ATP
binding site that is sufﬁciently good to allow the wild-type
enzyme to carry out moderately efﬁcient ATP-mediated
excision. As a consequence, it is relatively simple for the virus
to mutate in a way that enhances the ability of HIV-1 RT to
bind ATP appropriately and to carry out ATP-mediated
excision efﬁciently. In contrast, because HIV-2 RT does not
have a particularly good nascent ATP binding site, it is much
more difﬁcult for mutations to create an effective ATP
binding site. This makes the alternative pathway (AZT
resistance via the Q151M mutation) the more attractive
alternative for HIV-2, particularly because HIV-2 RT is,
relative to HIV-1 RT, less susceptible to incorporating AZTTP.
We found that HIV-1 RT has a lower Km and a higher kcat
for AZTTP than HIV-2 RT. However, HIV-1 RT also has a
lower Km and a higher kcat for dTTP than HIV-2 RT. Our data
were derived from the analysis of the incorporation of either
dTTP or AZTTP in a single cycle of incorporation assay; this
means the data can be compared directly. We suggest that the
fact that AZT is poorly phosphorylated within the cell could
make the difference in Km for AZTTP (0.17 lM for HIV-1 RT
versus 0.75 lM for HIV-2 RT) an important difference
because low levels of AZTTP within a cell would make the
Km for AZTTP a limiting factor. However, there is a
signiﬁcant problem in using this type of single-cycle kinetic
assay to try to understand the resistance or susceptibility of
HIV-1 or HIV-2 viruses to inhibition by AZT. The relative
efﬁciency of incorporating AZTTP and dTTP is quite
sequence-dependent [22], as is the excision reaction [23,24].
This means that kinetic assays done using any speciﬁc
sequence give data that may not reﬂect the ability of the
RT to incorporate (or excise) a particular nucleoside analog
(like AZT) and that assays that measure incorporation (and
excision) over several different sites give an average value that
more accurately reﬂects what happens when RT copies the
viral genome. Thus, the data in Figure 2 better reﬂects the
overall ability of HIV-1 RT and HIV-2 RT to differentiate
AZTTP and dTTP than do the kinetic data in Table 1.
In considering why HIV-1 RT prefers to use the excision
pathway and HIV-2 RT the Q151M exclusion pathway, we also
compared the region around Q151, and the positions where
there are secondary mutations that often accompany Q151M
in HIV-1 RT. The region around Q151 is involved in binding
the incoming dNTP and it is not surprising that this region is
(in terms of amino acid sequence) quite conserved in the two
RTs. However, when the unliganded structures are compared,
there are obvious differences in the positions of the amino
acids on the 113–118 segment. We do not yet have a ternary
structure of HIV-2 RT with a bound incoming dNTP, so it is
difﬁcult to know whether there are signiﬁcant differences in
the interactions of HIV-2 RT and the incoming dNTP. One of
the secondary mutations seen in HIV-1 RT, V75I, is present in
wild-type HIV-2 RT; moreover the secondary mutation that
appears to be the most signiﬁcant in HIV-1 RT, F116Y, would
not be expected, based on the available unliganded structure,
to have the same effect in HIV-2 RT that it has in HIV-1 RT.
High-level resistance to ddNTPs and AZTTP in HIV-1 RT
requires not only the Q151M mutation, but other secondary
mutations. Based on our in vitro data, it appears that in HIV-
2 RT, the Q151M mutation, along with the naturally
occurring I75 residue, is sufﬁcient to generate high-level
resistance to AZTTP. This is supported by the fact that wild-
type HIV-2 RT is already more resistant to AZTTP than is
wild-type HIV-1 RT or the HIV-1 RT variant Q151M (Figure
2). This difference has also been seen when the AZT
susceptibility of HIV-1 and HIV-2 viral replication were
compared [16]. If only one amino acid change is required to
generate high-level AZT resistance in HIV-2 RT via the
Q151M exclusion pathway, this would favor the Q151M
exclusion pathway in HIV-2 RT, while the fact that multiple
amino acid substitutions are needed to give high-level AZT
resistance in HIV-1 RT would mean that the Q151M pathway
would be less favored.
Another consideration is the fact that the Q151M mutation
requires two nucleotide changes (CAG to ATG). While it is
possible that the two changes could occur simultaneously, it is
more likely that the changes occur one base at a time. This
would require either a Q151L (CAG to CTG) or a Q151K
(CAG to AAG) intermediate. There may be differences in the
ability of the HIV-1 RT and HIV-2 RT to tolerate the
intermediate mutations that are needed to get to the ﬁnal
Q151M mutation. There are data that suggest that both of
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HIV-1 RT, which could make it difﬁcult for HIV-1 to generate
the Q151M mutation [25–27]. There are no published data on
the effects of the intermediate mutations at Q151 on HIV-2
RT activity; however, the Q151L mutant has been detected in
HIV-2–infected patients, suggesting that at least this mutant
may be less deleterious for HIV-2 RT than for HIV-1 RT
[11,14].
As has already been suggested, one way to look at the
problem is that HIV-1 RT, which readily incorporates
AZTTP, also has a relatively good nascent ATP binding site
and can be thought of as being part way along the pathway to
developing AZT resistance via excision. In contrast, wild-type
HIV-2 RT incorporates AZTTP less well and has a less well-
developed ATP binding site, so it can be considered to be
already on a pathway of becoming resistant by decreasing its
incorporation of AZTTP. Viewed in this light, the develop-
ment and exploitation of the excision pathway by HIV-1 RT
is, from the point of view of those trying to develop more
effective therapies, a very unfortunate coincidence. There is
no reason to think that the nascent ATP binding site that
HIV-1 RT exploits in the development of AZT resistance has
any important role in RT or reverse transcription in the
absence of AZT. This idea is reinforced by the data showing
that HIV-2 RT has a much less well-developed nascent ATP
binding site: if the ability to bind ATP for the purpose of
AZTMP excision was connected to some important under-
lying function, or had an important role in reverse tran-
scription, then this ATP binding site would likely be found in
HIV-2 RT, too. These observations also reinforce the
opportunistic nature of the evolutionary events that lead to
drug resistance in HIV-1 and HIV-2: modest differences in
the ability of the two wild-type enzymes to incorporate
AZTTP and to bind ATP and excise AZTMP cause them to
prefer different paths when they develop resistance to AZT,
an idea also proposed for the different NRTI resistance
mutations seen in HIV-1 RT [28].
Materials and Methods
Preparation of HIV-1 and HIV-2 RTs. The open reading frame
encoding wild-type HIV-1 RT (strain BH10) was cloned into a
plasmid-containing HIV-1 PR open reading frame as previously
described [5]. A similar plasmid encoding the open reading frame for
HIV-2 RT (strain ROD) and the HIV-2 PR was the generous gift of Dr.
Amnon Hizi (Tel Aviv University) and has been previously described
[17,18]. The plasmids are based on the expression vector pT5m, and
were introduced into the E. coli strain BL21 (DE3) pLysE. After
induction with isopropyl b-D-thiogalactopyranoside, the plasmids
express both the p66 forms of HIV-1 RT and HIV-1 PR, or the p68
form of HIV-2 RT and HIV-2 PR. Approximately 50% of the over-
expressed p66 HIV-1 RT or p68 HIV-2 RT is converted to the p51 or
p54 form by the co-expressed PR. The heterodimers accumulate in E.
coli and were puriﬁed by metal chelate chromatography [5].
Polymerase assays. The polymerase assays were done as previously
described [5]. For each sample, 0.25 lg of single-stranded M13mp18
DNA(New EnglandBiolabs,Beverly,Massachusetts, UnitedStates)was
hybridized to 0.5 ll of 1.0 OD/ml of the 47 sequencing primer (New
England Biolabs). The template/primer (T/P) was suspended in 100.0 ll
of 25 mM Tris (pH 8.0), 75 mM KCl, 8.0 mM MgCl2, 100.0 lg/ml BSA,
10.0 mM CHAPS, 2.0 mM DTT, 10.0 lM each of dATP, dTTP, dCTP,
and dGTP, and 2.0 lM[ a 
32P]dCTP. Extension was initiated by the
addition of 1.0 lg of wild-type RT. The mixture was incubated for 30
min at 37 8C, then the reaction was halted by the addition of 3 ml ice-
cold trichloroacetic acid. Precipitated DNA was collected by suction
ﬁltration through Whatman GF/C glass ﬁlters. The amount of
incorporated radioactivity was determined by liquid scintillation
counting. Inhibition of polymerization by AZTTP was done in a
similar manner, except that various concentrations of AZTTP were
added to the reaction. The activity of the enzyme was considered to be
100% in the absence of the AZTTP; the decreased level of
incorporated radioactivity in the presence of AZTTP was normalized
to this value.
Processivity assay. The processivity assay has been previously
described [5]. In brief, for each sample to be assayed, 0.5 ll of 1.0 OD/
ml  47 sequencing primer (New England Biolabs) was 59 end-labeled
with [c 
32P]ATP and T4 polynucleotide kinase. After puriﬁcation, the
labeled primer was annealed to single-stranded M13mp18 DNA (1.0 ll
ofa 0.25lg/ll DNAstockforeach sampleto be assayed)byheating and
slow cooling. The labeled T/P was resuspended in RT buffer, which is
25 mM Tris (pH 8.0), 75 mM KCl, 8.0 mM MgCl2, 100 lg/ml BSA, 10.0
mM CHAPS, and 2.0 mM DTT. One microgram of wild-type HIV-1 or
HIV-2 RT was added to each tube and allowed to bind to the labeled
template primer for 2 min. Extension was initiated by the addition of
dNTPs, to a ﬁnal concentration of 10.0 lM each, plus 0.5 U/ml
poly(rC) oligo(dG), which prevents RT from rebinding to the labeled
primer by binding the RT after it disassociates from the labeled T/P.
Pyrophosphorolysis. ATP- and NaPPi-dependent pyrophosphorol-
ysis analysis was done as previously described [5]. A synthetic DNA
oligonucleotide (59-GTCACTGTTCGAGCACCA-39) (Biosource, Ca-
marillo, California, United States) was 59 end-labeled, puriﬁed, then
annealed to the template (59-AATCAGTGTAGACAATCCCTAG-
CAATGGTGCTCGAACAGTGAC-39). The 39 end of the primer was
then blocked by the addition of AZTMP. After puriﬁcation of the
blockedT/P,theT/PwasincubatedinRTbufferwithHIV-1RTorHIV-
2 RT in the presence of variousconcentrations (described in the ﬁgure
legends) of either NaPPi or ATP for 15 min. The reactions were halted
by the addition of EDTA; the salts and nucleotides were removed by
passage through a CentriSep column (Princeton Separations, Adel-
phia, New Jersey, United States) and the T/P precipitated by the
addition of isopropyl alcohol. The products were fractionated on a
15% polyacrylamide sequencing gel. The total amount of T/P (blocked
and unextended plus deblocked and extended) and theamountof full-
length product (deblocked and extended to the end of the template)
were determined using a Phosphorimager.
Single dNTP incorporation kinetics. A synthetic oligonucleotide
primer was 59 end-labeled, puriﬁed, then annealed to the template as
described above. The labeled T/P was resuspended in polymerase
buffer (ﬁnal concentration of 15.0 nM T/P, 20.0 mM Tris [pH 8.0], 75.0
mM KCl, 16.0 mM MgCl2, 2.0 mM DTT, 0.1 mg/ml acetylated BSA, 10.0
mM CHAPS, 3.0 nM RT). The reactions were equilibrated at 37 8C for
5 min, then the reactions initiated by the addition of dTTP or
AZTTP. Final concentrations of the dNTPs ranged from 0.4 lMt o
200.0 lM. The reactions were allowed to proceed for 1.0 min, and the
reactions halted by the addition of EDTA; the salts and nucleotides
were removed by passage through a CentriSep column (Princeton
Separations) and the T/P precipitated by the addition of isopropyl
alcohol. The products were fractionated on a 15% polyacrylamide
sequencing gel. The product of the reaction is the amount of primer
extended by one nucleotide; the concentration of the product was
determined using a Phosphorimager. The concentration of substrate
[S] is the concentration of dNTP in the reaction, while velocity (v) is
the amount of product (nM of primerþ 1) generated in 1 min at the
given [S]. The data was plotted using the Woolf-Augustinsson-Hofstee
plot: v versus v/[S]. The line of best ﬁt was determined by linear
regression and the Vmax and Km were determined from the intercepts
of the plot.
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